Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity October 28, 2021
Webinar to be held Thursday, October 28, 2021 at 10 a.m. Eastern Time
MONTPELLIER, France, October 07, 2021– (BUSINESS WIRE) – Regulatory news:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that it will host a webinar on key opinion leaders on Thursday (KOL) on Cisplatin-Induced Ototoxicity, October 28, 2021 at 10:00 a.m. EST / 4:00 p.m. CET.
The webinar will include a presentation by thought leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview of hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current therapeutic landscape and the unmet medical need. in adults.
The Sensorion management team will also discuss the development of SENS-401 in cisplatin-induced ototoxicity. A question-and-answer session will follow the formal presentations.
SENS-401 is a leading drug candidate for the prevention and treatment of physical or chemical damage that results in the loss of sensory hair cells, including ototoxicity induced by cisplatin.
To register for the call, please click here.
Nicole C. Schmitt, MD, FACS, received her medical degree from Washington University School of Medicine in St. Louis, Missouri. She completed her internship in general surgery, a fellowship, and residency in otolaryngology at the University of Washington in Seattle, Washington. She also earned a Fellowship in Head and Neck Surgery and Tumor Biology at the University of Pittsburgh in Pittsburgh, Pennsylvania.
Dr Schmitt is a Head and Neck Surgical Oncologist and Scientist at Emory University in Atlanta, Georgia, United States. His research interests include tumor immunology and new combination therapies for head and neck cancer. Dr Schmitt has been studying the molecular mechanisms, incidence and prevention strategies of cisplatin-induced ototoxicity since 2007. Dr Schmitt is a fellow of the American College of Surgeons, American Academy of Otolaryngology Head and Neck Surgery and the American Head and Neck Society. .
Sensorion is a pioneering clinical-stage biotechnology company specializing in the development of new therapies to restore, treat and prevent hearing loss disorders. Its clinical-stage portfolio includes a phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to broaden its understanding of the pathophysiology and etiology of inner ear diseases, enabling it to select the best targets and modalities for drug candidates. The Company is also working to identify biomarkers to improve the diagnosis of these underserved diseases. Sensorion has launched three gene therapy programs, currently at the preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation in the gene encoding Otoferlin, hearing loss linked to the target gene GJB2 as well as the syndrome. Usher Type 1 to potentially treat important segments of hearing loss in adults and children. The Company is potentially in a unique position, through its platforms and portfolio of potential therapies, to have a lasting positive impact on hundreds of thousands of people with inner ear disorders, a significant global medical need not satisfied.
IS IN: FR0012596468
This press release contains certain forward-looking statements regarding Sensorion and its activities. These forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that these forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set out in the 2020 annual financial report published on April 9, 2021 and available on our website and to changing economic conditions, financial markets and markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or currently considered to be immaterial by Sensorion. The occurrence of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Sensorion to differ materially from these forward-looking statements. This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe to Sensorion shares in any country whatsoever. The distribution of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release should inform themselves about and comply with these local restrictions.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211006005987/en/
+33 6 27 74 74 49
Head of Investor Relations & Communication
+ 33 6 72 18 00 22